Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors

2004 ◽  
Vol 27 (1) ◽  
pp. 6-11 ◽  
Author(s):  
F. Panzuto ◽  
C. Severi ◽  
R. Cannizzaro ◽  
M. Falconi ◽  
S. Angeletti ◽  
...  
Keyword(s):  
Pancreatic Polypeptide ◽  
Plasma Levels ◽  
Chromogranin A ◽  
Endocrine Tumors ◽  
Pancreatic Endocrine Tumors ◽  
Combined Use

Chromogranin A: Is It a Useful Marker of Neuroendocrine Tumors?

2007 ◽  
Vol 25 (15) ◽  
pp. 1967-1973 ◽  
Author(s):  
Davide Campana ◽  
Francesca Nori ◽  
Lidya Piscitelli ◽  
Antonio Maria Morselli-Labate ◽  
Raffaele Pezzilli ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Plasma Levels ◽  
Chromogranin A ◽  
Imaging Techniques ◽  
High Specificity ◽  
Endocrine Tumors ◽  
Cell Hyperplasia ◽  
Specificity And Sensitivity ◽  
Ecl Cell ◽  
Number Of Patients

Purpose We evaluated the pattern of chromogranin A (CgA) plasma levels in a large number of patients with neuroendocrine tumors (NETs), in a series of patients with chronic atrophic gastritis (CAG) with and without enterochromaffin-like (ECL) cell hyperplasia, and in healthy participants (HPs). Patients and Methods Two hundred thirty-eight patients with NETs, 42 patients with CAG with or without ECL cell hyperplasia, and 48 HPs were studied. All patients underwent a baseline visit, biochemical routine check-up, imaging techniques, endoscopy, and histologic determination. Results CgA plasma levels were higher in patients with NETs compared with CAG patients or HPs (P < .001). In the NET group, we observed higher CgA levels in patients with diffuse disease compared with patients with local or hepatic disease (P < .001). CgA plasma levels were significantly higher in patients with Zollinger-Ellison syndrome compared with other types of endocrine tumors (P < .001). We found the best cutoff range between HPs and NET patients to be 18 to 19 U/L (sensitivity, 85.3%; specificity, 95.8%). Comparing all participants without neoplasia (HPs, CAG patients, and disease-free patients) and patients with endocrine tumors, the best cutoff range was 31 to 32 U/L (sensitivity, 75.3%; specificity, 84.2%). Setting the specificity at 95%, the cutoff range was 84 to 87 U/L (sensitivity, 55%). Conclusion Our study confirms the high specificity and sensitivity of CgA in diagnosing an endocrine tumor. It is necessary to use a cutoff range of 84 to 87 U/L to obtain a high specificity in diagnosing NETs, with the aim of excluding patients in whom the CgA was elevated as a result of other non-neoplastic diseases.

Secretion of Pancreatic Polypeptide in Patients with Pancreatic Endocrine Tumors

1986 ◽  
Vol 315 (5) ◽  
pp. 287-291 ◽  
Author(s):  
Thomas E. Adrian ◽  
Lars O. Uttenthal ◽  
Susan J. Williams ◽  
Stephen R. Bloom
Keyword(s):  
Pancreatic Polypeptide ◽  
Endocrine Tumors ◽  
Pancreatic Endocrine Tumors

High sensitivity of combined plasmatic chromogranin A (CgA) and pancreatic polypeptide (PP) as markers of digestive endocrine tumors (dET)

2001 ◽  
Vol 120 (5) ◽  
pp. A762
Author(s):  
Francesco Panzuto ◽  
Renato Cannizzaro ◽  
Stefano Angeletti ◽  
Alessandra Moretti ◽  
Vito Domenico Corleto ◽  
...  
Keyword(s):  
Pancreatic Polypeptide ◽  
Chromogranin A ◽  
High Sensitivity ◽  
Endocrine Tumors

High sensitivity of combined plasmatic chromogranin A (CgA) and pancreatic polypeptide (PP) as markers of digestive endocrine tumors (dET)

2001 ◽  
Vol 120 (5) ◽  
pp. A762-A762
Author(s):  
F PANZUTO ◽  
R CANNIZZARO ◽  
S ANGELETTI ◽  
A MORETTI ◽  
V CORLETO ◽  
...  
Keyword(s):  
Pancreatic Polypeptide ◽  
Chromogranin A ◽  
High Sensitivity ◽  
Endocrine Tumors

Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study

2003 ◽  
Vol 98 (11) ◽  
pp. 2435-2439 ◽  
Author(s):  
Lucio Gullo ◽  
Marina Migliori ◽  
Massimo Falconi ◽  
Paolo Pederzoli ◽  
Rossella Bettini ◽  
...  
Keyword(s):  
Clinical Study ◽  
Endocrine Tumors ◽  
Pancreatic Endocrine Tumors ◽  
Multicenter Clinical Study

scholarly journals Pancreatic endocrine tumors

2011 ◽  
Vol 24 (S2) ◽  
pp. S66-S77 ◽  
Author(s):  
Sylvia L Asa
Keyword(s):  
Endocrine Tumors ◽  
Pancreatic Endocrine Tumors

Pancreatic Endocrine Tumors

2007 ◽  
Vol 36 (2) ◽  
pp. 431-439 ◽  
Author(s):  
Niraj Jani ◽  
A. James Moser ◽  
Asif Khalid
Keyword(s):  
Endocrine Tumors ◽  
Pancreatic Endocrine Tumors

scholarly journals Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1Cin pancreatic endocrine tumors

BMC Cancer ◽  
2011 ◽  
Vol 11 (1) ◽  
Author(s):  
Giorgio Malpeli ◽  
Eliana Amato ◽  
Mario Dandrea ◽  
Caterina Fumagalli ◽  
Valentina Debattisti ◽  
...  
Keyword(s):  
Endocrine Tumors ◽  
Down Regulation ◽  
Pancreatic Endocrine Tumors

Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors

2009 ◽  
Vol 40 (1) ◽  
pp. 30-40 ◽  
Author(s):  
Stefano La Rosa ◽  
Catherine Klersy ◽  
Silvia Uccella ◽  
Linda Dainese ◽  
Luca Albarello ◽  
...  
Keyword(s):  
Endocrine Tumors ◽  
Prognostic Evaluation ◽  
Pancreatic Endocrine Tumors
Sign in / Sign up

Export Citation Format

Share Document